Upgrade to SI Premium - Free Trial

Fate Therapeutics (FATE)

2.08 -0.09 (4.15%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (Posted A/C)

Latest Headlines

Fate Therapeutics shares Phase 1 FT819 data for lupus nephritis October 26, 2026 7:02 AM - StreetInsider Fate Therapeutics Presents Updated Preliminary Data for FT819 in Active Lupus Nephritis at American Society of Nephrology Kidney Week 2026 October 26, 2026 7:00 AM - StreetInsider Fate Therapeutics names Jamie Harrell SVP of commercial operations October 12, 2026 7:00 AM - StreetInsider Fate Therapeutics Appoints Jamie Harrell as Senior Vice President, Market Development & Commercial Operations to Lead the Commercialization of CAR T-cell Therapies October 12, 2026 7:00 AM - Globe NewsWire Fate Therapeutics names Jamie Harrell as commercial operations chief October 12, 2026 7:00 AM - StreetInsider Fate Therapeutics Appoints Jamie Harrell as Senior Vice President, Market Development & Commercial Operations to Lead the Commercialization of CAR T-cell Therapies October 12, 2026 7:00 AM - StreetInsider Entera Bio adds former Gilead executive Laura Hamill to its board October 6, 2026 8:00 AM - StreetInsider Entera Appoints Global BioPharma Executive Laura Hamill to Its Board of Directors, Expanding Commercial Expertise October 6, 2026 8:00 AM - StreetInsider Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) October 2, 2026 7:00 AM - StreetInsider Fate Therapeutics to Participate in Upcoming Fourth Quarter 2026 Conferences October 1, 2026 7:00 AM - StreetInsider Form 8-K FATE THERAPEUTICS INC For: Sep 25 September 28, 2026 8:11 AM - SEC Filing Fate Therapeutics gets $15M CIRM grant for lupus nephritis trial September 25, 2026 7:00 AM - StreetInsider Fate Therapeutics Announces Receipt of California Institute for Regenerative Medicine (CIRM) CLIN2 Grant to Advance RECLAIM-LN September 25, 2026 7:00 AM - StreetInsider Fate Therapeutics Selected for Four Presentations Highlighting its Off-the-Shelf CAR T-Cell Portfolio in Autoimmune Disease at ACR Convergence 2026 September 16, 2026 7:00 AM - StreetInsider Fate Therapeutics to present FT819 CAR T-cell data at CCR-West September 9, 2026 7:01 AM - StreetInsider Fate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR – West 2026 Meeting September 9, 2026 7:00 AM - StreetInsider Fate Therapeutics to Participate in Fireside Chat at the 2026 Annual Cantor Global Healthcare Conference September 3, 2026 7:00 AM - StreetInsider Fate Therapeutics (FATE) PT Raised to $3.50 at Wells Fargo August 14, 2026 8:52 AM - StreetInsider Fate Therapeutics (FATE) PT Raised to $8 at Piper Sandler August 14, 2026 8:26 AM - StreetInsider Fate Therapeutics starts Phase 2 lupus nephritis trial of FT819 August 14, 2026 7:00 AM - StreetInsider Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis August 14, 2026 7:00 AM - StreetInsider Form S-8 FATE THERAPEUTICS INC August 13, 2026 4:08 PM - SEC Filing Form 10-Q FATE THERAPEUTICS INC For: Jun 30 August 13, 2026 8:34 AM - SEC Filing Form 8-K FATE THERAPEUTICS INC For: Aug 13 August 13, 2026 8:32 AM - SEC Filing Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates August 13, 2026 8:30 AM - StreetInsider Form 4 FATE THERAPEUTICS INC For: Aug 04 Filed by: TAHL CINDY August 5, 2026 4:05 PM - SEC Filing Form 4 FATE THERAPEUTICS INC For: Aug 04 Filed by: Valamehr Bahram August 5, 2026 4:02 PM - SEC Filing Form 144 FATE THERAPEUTICS INC Filed by: TAHL CINDY August 4, 2026 4:40 PM - SEC Filing Form 144 FATE THERAPEUTICS INC Filed by: Valamehr Bahram August 4, 2026 4:35 PM - SEC Filing Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) August 3, 2026 4:05 PM - StreetInsider Full Article List